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E-mail address: vorlando@dti.telethon.it (V. OrlandDuring development cell differentiation is accompanied by progressive restriction of the develop-
mental potential and increased structural and functional specialization of cells. In this context,
mechanisms of cell memory guarantee that cells maintain different identities previously deter-
mined by the integrated action of signalling and speciﬁc sets of transcription factors. Unraveling
the molecular basis by which cells build and maintain their memory represents one of the most fas-
cinating problems in biology. PcG proteins were originally identiﬁed as part of an epigenetic cellular
memory system that controls gene silencing via chromatin structure. However, recent reports sug-
gest that they are also involved in controlling dynamics and plasticity of gene regulation, particu-
larly during differentiation, by interacting with other components of the transcriptional
apparatus. In this review, we discuss the role of PcG proteins in pluripotent ES cells and in well
known mammalian cell differentiation systems including skeletal muscle, epidermal, neuronal dif-
ferentiation. The emerging picture suggests that indeed, plasticity and not rigidity is a fundamental
aspect of PcG physiology and cell memory function.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The ability to partition the genome into sets of active and qui-
escent genes and to subsequently maintain this partitioning
through many cell divisions, underlies the process of cellular dif-
ferentiation, which is essential for all multicellular life forms. Cel-
lular differentiation is a natural event in every organism. Within an
organism, hundreds of different cell types are deﬁned by the un-
ique subset of information they transcribe from a genome held in
common. This cellular identity is maintained during development
and in adulthood, by perpetuating patterns of gene expression
through rounds of cell division. How is this cellular memory main-
tained and how can the cells with identical genetic patterns be dif-
ferent from each other? As such, a single genome may be modiﬁed
to produce multiple epigenomes allowing for cellular diversity, a
necessary criterion for the development of metazoans. The non
coding ‘‘epigenome’’ contributes to the quality, stability and herita-
bility of cell-speciﬁc transcription programs using different levels
of control: DNA methylation, histone modiﬁcations, nucleosome
mobility, domain organization, in trans interactions, nuclear orga-
nization that ensure the transmission of the epigenetic patterns
and underlying transcription states from one cell to the daughter
cells.
During cell differentiation or metabolic switch, cells undergo
profoundchanges ingeneexpression. Theseevents are accompaniedcal Societies. Published by Elsevier
o).by complex modiﬁcations of chromosomal components and
nuclear structures, including covalent modiﬁcations of DNA and
chromatin up to topological reorganization of chromosomes and
genes in the nucleus. To various extents, all these levels of organiza-
tion contribute to the stability and heritability of transcription
programmes and deﬁne what is meant as the epigenomic level
of gene regulation. Thus, epigenetic modiﬁcations inﬂuence gene
expressionpatterns andprovideaunique signatureof a cell differen-
tiation status.
Polycomb Group (PcG) genes code for chromatin multipro-
tein complexes that exert essential memory function during
developmental and adulthood stages. Together with a battery of
components including sequence-speciﬁc DNA binding/accessory
factors, signalling pathway intermediates and non-coding RNA
(ncRNA), PcG proteins maintain cellular identity homeostasis by
setting heritable chromatin states to prevent changes in gene
silencing programs [1]. The overall picture is that, in any given
cell type, most alternative genetic programs are shut down by
PcG proteins, except for the subset that is required in that cell
type. Notably, PcG memory function is not merely conservative
but also includes the ability of cells to dynamically respond to
environmental cues. Indeed, current knowledge about the role
of PcG proteins in the context of complex differentiation
processes extends cell memory concept towards a more dynamic
vision in which PcG appear to modulate silencing and also be
involved in the establishment of transcriptional competence of
promoter regions during differentiation. In this review, we focus
on the role of the PcG proteins as epigenetic regulators of cellB.V. Open access under CC BY-NC-ND license.
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perspective, we review the role of PcG proteins in pluripotent
cells and in three well characterized differentiation systems,
namely skeletal muscle, epidermal and neuronal cells aiming at
a synthesis of the mechanistic principles governing chromatin
regulation by this intriguing group of epigenetic functions. Final-
ly, we address some of the apparent contradictions of the differ-
entiation mechanisms, analyzing the opposite aspects of stability
and plasticity of these processes, brieﬂy focusing on the role of
PcG during reversible somatic cell reprogramming.2. Epigenome and cell identity diversity: some general aspects
During development cell differentiation consists of the progres-
sive restriction of the developmental potential and increased struc-
tural and functional specialization of cells, leading to the formation
of specialized cells, tissues and organs. In adult tissues, differenti-
ation is a common process in which tissue speciﬁc adult stem cells
guarantee organ homeostasis as well as tissue repair. This process
involves highly controlled modiﬁcations in gene expression and
selective repression of other cell type speciﬁc genes. With few
exceptions, cellular differentiation almost does not involve a
change in DNA sequence itself. Thus, different cell types display
different morphological and functional characteristics despite hav-
ing the same set of coding genome.
At the chromosomal level, diversity appears to rely on different
sets of epigenetic signatures that mark regulatory elements to
specify the functional state of tissue speciﬁc genes and help to
maintain cell type speciﬁc transcription programs. However, to
date the complete dynamics and role of the epigenome during cell
differentiation and possibly dedifferentiation is not understood.
Both processes have profound implications also for diseases in
which cell identity is compromised (e.g. cancer) as well as repro-
gramming as it may matter for tissue regeneration.3. Memory of cell identity
During development, cells after acquiring different identities
under the action of speciﬁc sets of transcription factors must
remain different after the original combination of signalling and
transcription cues responsible for cell diversiﬁcation have left the
stage. To unravel the molecular basis by which cells build and
maintain their memory represents one of the most fascinating
problems in biology.
In the context of cell determination, three broad categories of
cell memory can be distinguished which may be called cytoplas-
matic, autocrine and nuclear memory. The ﬁrst mechanism is
related to components encoded by a set of active gene products
that are present in the cytoplasm and act back on the genome,
directly or indirectly, to maintain the selective expression of that
speciﬁc set of genes. The second one is a variant of the cytoplasmic
memory as it depends on a positive loop, but with the special fea-
ture that its products are secreted into the extracellular environ-
ment and feed back on signalling components of the cell surface.
In contrast, ‘‘nuclear memory’’ depends on self-sustaining changes
that are intrinsic to the chromatin-changes that deﬁne the selec-
tion of genes to be expressed and yet leave the DNA sequence unal-
tered. By changing chromatin structure, chromatin modiﬁers alter
the accessibility of a gene to the transcriptional machinery and
promote either its activation or its silencing. At cell division, cells
use the epigenome to ﬁx memory of earlier determined transcrip-
tion states and ensure their perpetuation after cell division.
Chromatin modiﬁcations, hence the epigenome, play a key role in
this process.4. Polycomb group genes: master controllers of cell memory
Discovery and investigation of PcG gene silencing memory
system, and its activators counterpart the Trithorax group (TrxG)
substantially contributed to our current understanding of how
cells remember who they are in time and space. Polycomb group
genes were discovered in Drosophila melanogaster in the context
of a large genetic screen aimed at the identiﬁcation of anterior–
posterior segmental regulators of Hox gene silencing [2,3]. The
cloning of Polycomb protein revealed a region of homology with
heterochromatin protein 1 (Hp1) hence coined ‘‘chromodomain’’
(chromatin-modiﬁer-domain) [4]. For these reasons, PcG proteins
were originally proposed to be part of a cellular memory system
that stably locks Hox gene expression states via chromatin struc-
ture [5].
Recent genome-wide studies have shown that PcG proteins
control several hundreds of genes regulating most signalling and
developmental pathways [6–8], cell cycle [9], spermatogenesis
[10], cytoskeleton [11], cellular senescence [12], X-chromosome
inactivation [13,14], genomic imprinting [15–17], stem cell plastic-
ity and cell fate determination, as well as tumor progression
[18,19]. Of note, PcG proteins do not solely control silencing via
chromatin structure but they are involved also in controlling dy-
namic and plasticity of gene regulation by interacting with other
components of transcription apparatuses. Indeed, active PcG target
genes can be re-repressed or be activated or exist in intermediate
states. Thus, PcG memory function involves also the ability to
respond to signalling and to regulate the balance between gene
silencing and switch.
PcG proteins are found in multiprotein complexes, including the
Polycomb Repressive Complexes PRC1 and PRC2. Two other PcG
complexes were characterized in Drosophila, Pho-Repressive Com-
plex (PhoRC) and Polycomb Repressive Deubiquitinase (PR-DUB),
and their components have orthologues in mammals [20–23]. An
important emerging theme is that there are multiple versions of
PRC1 and PRC2, with mounting evidence that alternative subunit
compositions may confer distinct target gene speciﬁcity [24–26].
Polycomb mediated gene silencing rely mostly on the regulation
of chromatin structure, through post-translational modiﬁcations
(PTM) of histones. PRC2 complex is responsible for the methylation
(di- and tri-methylation) of Lys 27 of histone H3 (H3K27me2/3)
[23,27] through its enzymatic subunits Ezh2 and Ezh1, whereas
the PRC1 complex monoubiquitylates Lys 119 of histone H2A
(H2AK119ub) via the ubiquitin ligases Ring1A and Ring1B. In addi-
tion, some PRC1 complexes can regulate gene expression by com-
pacting chromatin in a manner independent of its enzymatic
activity [28]. PRC1 component PC, known as Cbx in mammals,
binds speciﬁcally to the product of PRC2 catalysis, H3K27me3,
leading to the hypothesis that PRC1 functions downstream of
PRC2. However some genes targeted by PRC2 lack H2AK119ub
[29] and genes targeted by PRC1 may not contain PRC2 compo-
nents [30,31]. These data suggest that PcG signature is complex
and each gene may contain just part of it, depending on its history
and also speciﬁc regulation [1,23,27,32–34].
A recurring question in the study of PcG mechanisms is how the
complexes are recruited to their target genes. While several
Polycomb Response Elements (PREs), deﬁned as epigenetic DNA
modules that silence promoters at distance in a PcG-dependent
manner have been studied in detail in Drosophila [35–38], in mam-
mals it remains unclear to what extent DNA sequence plays a role
in PcG targeting. Search for mammalian PREs appears to be difﬁcult
and has only led to isolated successes [30,39]. Recently, it has been
recognized that PcG can physically interact with non-coding RNA
[40–43], providing another mechanism for sequence speciﬁc
targeting. Since many issues remain unsettled about PREs and
recruiters, more work is needed to deﬁne the rules for PcG target-
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to better clarify the mechanisms that govern the dynamic states of
PcG target genes, the recruitment of PcG complexes and the
switches that occur when the transcriptional readout of these tar-
get genes changes.
5. Polycomb repressive complexes in embryonic stem cells
Stem cells, or more properly pluripotent cells, are classically
deﬁned as cells that can both self-renew and generate progeny able
to enter multiple differentiation programs. In the case of embry-
onic pluripotent stem (ES) cells, the range of lineage options com-
prises every type of tissue that is found in the adult animal. For
adult stem cells, this range is restricted; for example, as we
described in the following paragraphs, neural stem cells generate
various neuronal and glial populations, epidermal lineage origi-
nates from a single layer of multi-potent progenitors, the commit-
ted muscle cells, the myoblasts, differentiate and fuse into
multinucleated myotubes to ﬁnally maturate into myoﬁbers. Three
transcription factors, Oct4, Sox2 and Nanog, cooperate to ensure
the self-renewal and pluripotency of ES cells [44,45]. The careful
balance of transcriptional regulators and epigenetic factors is
responsible for the crucial genomic plasticity proper of ES cells.
Polycomb group proteins are among the chief epigenetic regulators
that maintain pluripotency and also set the stage for transition to
diverse differentiation programs. Depletion of Ezh2, Suz12 and
Eed, the three core components of PRC2 complex, results in early
embryonic lethality in mice [46–48]. Interestingly, analysis of
Ezh2-/- ESCs suggests existence of an additional enzyme(s) catalyz-
ing H3K27 methylation. Shen et al. [49] identiﬁed Ezh1 as a PRC2
component able to mediate H3K27me3 and to complement Ezh2
in maintaining stem cell identity and executing pluripotency
[50–52]. Conversely, PRC1 deﬁciency is associated with less severe
phenotype as the progeny is in general viable but exhibits transfor-
mations or other developmental abnormalities [53–55]. Ring1B is
the unique PRC1 component that shows embryonic lethality after
its knockdown, due to gastrulation defects [28,56]. Interestingly,
the components of both PRC1 and PRC2 are required for differenti-
ation and lineage commitment but they are not necessary for ES
cell self-renewal [57,58]. PcG mutant ES cells can still self-renew,
maintain normal morphology and express Oct4, Sox2 and Nanog
[57–59]. Moreover, although the PcG knockout ES cells do not
differentiate efﬁciently into the three germ layers, they can still
contribute to their formation, in vivo and in vitro [57–59].
However, loss of individual PRC components in ES cells does not
lead to increased expression of lineage-afﬁliated genes and
unscheduled differentiation [57,58,60], an effect that is even more
pronounced in ES cells carrying targeted deletions of both PRC1
and PRC2 [59]. These data demonstrate an unexpected redundancy
between PRC1 and PRC2 during the formation of differentiated
cells, suggesting that PcG system is critical for ﬁne-tuning gene
expression and that epigenetic patterns required to progress
through differentiation cannot be set up in the absence of PcG
regulation.
Six independent research groups identiﬁed Jarid2 as a previously
unreported component of PRC2 in ESCs [24–26,61–63]. Interest-
ingly, Jarid2 contains a Jumonji C domain (demethylase) but it
is devoid of detectable histone demethylase activity. Indeed, the
role of this PRC2 component appears to be quite complex. It co-
localizes with PRC2 and H3K27me3 on the chromatin and modu-
lates the function of this PcG complex in ESCs. Genome-wide
ChIP-seq analysis of Jarid2, Ezh2 and Suz12 binding reveals that
Jarid2 and PRC2 occupy the same genomic regions [26,61]. Jarid2
is required for efﬁcient binding of PRC2, indicating that the inter-
play of PRC2 and Jarid2 ﬁne-tunes deposition of the H3K27me3
mark. However, evidence was reported for a different role of Jarid2in pluripotent ES in regulating RNA Pol II recruitment at bivalent
genes [24]. This novel function for PcG protein suggest that PcG
memory is required not only to prevent changes in gene expression
but also to set the stage and provide competence for switching by
regulating RNA Pol II at promoters [24,64]. Thus, the precise role of
Jarid2 in ES remains to be elucidated.
Recent advances suggest that non-coding RNAs play a key role
in the recruitment of PcG complexes in ES cells. DNA microarray
analysis showed that short ncRNAs (6 200 nt) were transcribed
from the 50 end of several hundred PcG target genes in ES cells
[65]. Interestingly, these ncRNAs interact with PRC2 and are
involved in stabilizing PRC2 association with chromatin. Moreover,
the ncRNAs were depleted from PcG target genes that are de-
repressed during differentiation [65]. This indicates that short
ncRNAs might function as the interface between DNA and speciﬁc
chromatin remodelling activities, though the importance of direct
base pairing at speciﬁc sequence motifs is still unknown. Aside
short RNA, also long ncRNA appears to be an integral component
of PRC2 complex [40,43]. Deep-sequencing analysis of PRC2 associ-
ated RNA revealed an unexpected complexity with several hun-
dreds candidate RNA moieties being potentially involved in PRC2
function [43]. An open question is whether these RNA act in cis
or in trans. In the case of X-chromosome inactivation PRC2 binds
Xist RNA [66]. Long intergenic non-coding RNA (lincRNA) encoded
in the mouse HoxB clusters is required for PRC2 dependent silenc-
ing of HoxD cluster [67]. Notably, interaction with ncRNA appears
to be cell cycle regulated [68].
Mendenhall et al. [69] demonstrate a causal role for GC-rich se-
quences in PRC2 recruitment and implicate a speciﬁc subset of CpG
islands depleted of activating motifs as instrumental for the initial
localization of this key regulator in mammalian genome. Several
studies, included the four discussed above, reported the identiﬁca-
tion of a Pcl2/Mtf2 containing PRC2 complex in ESCs
[24,25,62,70,71]. Pcl2, one of the three homologs of Drosophila
Polycomb-like, functions as a bona ﬁde PcG protein. Indeed
Pcl2-PRC2 occupies a subset of PcG target genes in ESCs in similar
pattern as PRC2 [25,70,71] and appears to promote H3K27 trime-
thylation [70,71]. On the basis of the gene expression effects upon
Pcl depletion in ESCs, the authors speculate that Pcl2/PRC2 may
function to regulate self-renewal to enable an appropriate
response to differentiation cues. Considering these observations
together, the overall picture is that diversity of Polycomb com-
plexes could reﬂect functional consequences on gene expression
as well as biological output.
Precise localization of PRC1 and PRC2 within the genome is
necessary to facilitate those speciﬁc changes in chromatin and
gene expression that accompany lineage commitment. Genome-
wide studies of PRC1 and PRC2 in ES cells have shown that they
target promoters of >2000 genes, of which a large subset overlaps
with target genes of Oct4, Nanog and Sox2 [6,8]. PcG proteins co-
occupy and regulate the expression of a large cohort of develop-
mental and signalling genes in ESCs, such as the Hox gene cluster
as well as members of the Dlx, Fox, Irx, Lhx, Pou, Sox, Tbx, and
Wnt gene family [6,8,29]. Interestingly, it has been reported that
H2AZ histone variant is enriched at PcG complex target genes in
ES cells and is necessary for lineage commitment [72]. Moreover,
a recent work showed that a subset of PcG-target genes is bound
and regulated in response to altered c-Myc levels [73]. Bernstein
and colleagues [74] identiﬁed a novel chromatin pattern in ESCs,
the ‘‘bivalent domains’’, that harbors both the ‘‘repressive’’
H3K27me3 and the ‘‘activating’’ H3K4me3 modiﬁcations (Fig. 1)
[75–77]. Bivalent domains are not, however, exclusive of pluripo-
tent stem cells. They can also be found in cells of restricted
potency, including T cells and ﬁbroblasts, where genes are unlikely
to be poised in preparation for subsequent activation [75,77–81].
This ‘‘contradictory’’ chromatin pattern is consistent with the idea
Fig. 1. PcG and chromatin bivalent domains. In ES and other lineage committed precursor cells, promoters of a wide range of non-transcribed developmental genes are
characterized by a particular chromatin pattern that harbors both the ‘‘repressive’’ H3K27me3 and the ‘‘activating’’ H3K4me3 modiﬁcations. Such ‘‘bivalent promoters’’,
contain a speciﬁc, non-elongating RNA Pol II isoform phosphorylated at Serine 5. This state ﬁxes genes in transcription competent, ‘‘poised state’’, and constitutes an
important regulatory step for genes that have to accommodate dynamic transcriptional responses to developmental cues. Bivalent domains are generally resolved during
differentiation into either H3K4me3 (A) or H3K27me3 (B) regions depending on the expression state of the gene in a particular cell type. Considering the PcG targets, the
bivalent domains can be divided in two classes-the ﬁrst occupied by both PRC2 and PRC1 and the second speciﬁcally bound by PRC2 (B).
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coordinated by the concerted activities of TrxG and PcG proteins.
Despite the concept that H3K4me3 is associated with transcrip-
tional activation, bivalent genes display low expression levels.
Such bivalent promoters contain a speciﬁc RNA Pol II isoform phos-
phorylated at Serine 5 (RNA Pol II S5) [82,83]. Also, PcG repressed
promoters do not exclude RNA Pol II complex [84]. Indeed, recent
genome-wide studies in Drosophila show that RNA Pol II binds
transcription start sites of a large number of silent, developmen-
tally regulated genes [83,85], suggesting that stalling RNA Pol II
is an important regulatory step for genes that have to accommo-
date dynamic transcriptional responses to developmental cues. A
similar picture is also characteristic of human cells [86]. In this
context, it is highly relevant that Ring1 proteins play a decisive role
in maintaining stalled RNA Pol II at promoters of bivalent domains
of ES cells [82]. Thus the interplay between PcG and basal tran-
scription machinery may be an integral part of cell memory.
Bivalent domains are generally resolved during differentiation
into either H3K27me3 or H3K4me3 regions depending on the
expression state of the gene in a particular cell type (Fig. 1). Ku
et al. [29] found that bivalent domains can be divided in two
classes-the ﬁrst occupied by both PRC2 and PRC1 and the second
speciﬁcally bound by PRC2. PRC1/PRC2 positive bivalent domains
appear functionally distinct as they more efﬁciently retain
H3K27me3 upon differentiation, show stringent conservation of
chromatin state and associate with an overwhelming number of
developmental regulator gene promoters (Fig. 1) [29]. Thus, the
binding of PcG proteins in ESCs may facilitate repression at a
particular set of genes during differentiation by using different
stable silencing mechanisms, such as DNA methylation [23,87].
Indeed, promoters associated with H3K27me3 in ESCs are more
likely to become DNA methylated during differentiation [80,88].
The resolution of bivalent domains is also probably facilitated by
a class of histone demethylases that selectively remove
H3K4me3, consistent with their essential roles in development
and differentiation [89,90]. Conversely, loss of PRCs or H3K27me3
may facilitate the activation of genes necessary for lineage commit-ment. Two histone demethylases, Jmjd3 and UTX are necessary
for proper development and differentiation in a variety of mamma-
lian systems and are targeted to developmental regulators such as
Hox genes during ESCs differentiation [91,92]. Therefore, demeth-
ylation of H3K27me3 may be one way to disrupt PcG-mediated
gene repression, although there are probably other mechanisms
that work in concert such as those mediated by signalling path-
ways in response to developmental cues (Fig. 2) [93–95]. Thus,
the potential discovery of mechanisms that govern the dynamics
and the recruitment of PcG proteins to target sites in the genome
may facilitate efforts to direct differentiation of stem cells in vitro
and to control disease progression in vivo.6. PcG-mediated epigenetic control of skeletal muscle
differentiation
Vertebrate skeletal muscle formation constitutes an excellent
system to study the signals and the molecular mechanism that
govern cellular differentiation. Myogenesis is a multistep process,
which begins with the commitment of multipotent mesodermal
precursor cells to pursue muscle fate. These committed cells, the
myoblasts, then differentiate and fuse into multinucleated myotu-
bes to ﬁnally give rise to the syncytium of multinucleated cells to
organize myoﬁbers. The speciﬁcation, proliferation and terminal
differentiation of skeletal muscle cells is controlled by several tran-
scription factors that interact with enzymes modifying the nucleo-
somes structure to control the regulated formation and
recruitment of speciﬁc protein complexes to muscle gene loci
[33,96,97]. First evidence of the involvement of PcG proteins in
the control of this differentiation system derives from the work
of Laible et al. who reported the identiﬁcation and phenotypic
analysis of mammalian E(z) SET domain homologue [98]. In ES
cells, the silent master gene MyoD locus is occupied by PcG
proteins although bivalently marked by H3K27me3 and the trxG
H3K4me3 modiﬁcations [8]. Subsequently, in skeletal muscle cell
precursor cells, the MyoD locus is no longer occupied by PcG
Fig. 2. Different mechanisms of promoter de-repression by PcG displacement. To permit gene activation, PcG complexes and the repressive mark H3K27me3 have to be
displaced from their target genes. Different epigenetic pathways have been proposed, in various differentiation systems, that would contribute to switching transcriptional
program. One way is the recruitment of chromatin remodelling complexes on target genes (A). For example, during muscle differentiation, the p38 MAPK pathway is essential
for the recruitment of SWI/SNF chromatin remodelling complex to the Myog and CKm promoters. Another mechanism by which lineage speciﬁc genes repressed by PcG-
mediated H3K27me3 become derepressed in differentiated cells postulates the existence of speciﬁc H3K27me3 demethylases (B). Alternatively, a phospho/methyl switch
mechanism has been reported to explain PcG removal from the chromatin. Phosphorylation of H3Serine28, via mitogen and stress activated kinases Msk1/2, is able to
counteract the docking site H3K27me3 determining the PcG chromatin displacement and gene activation, in response to stress signalling, mitogenic signalling and retinoic
acid (RA)-induced neuronal differentiation (C).
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However, while MyoD is expressed in proliferating myoblasts,
certain MyoD target genes although occupied by PcG protein are
marked by H3K27me3 and kept in standby position for subsequent
activation. After additional signals initiate the myogenic program
PcG binding and H3K27me3 are lost at MyoD target loci, resulting
in appropriate muscle gene expression and skeletal muscle cell
differentiation. Caretti et al. [99] proposed a two-step activation
model to deﬁne PcG dependent muscle gene expression and cell
differentiation. In undifferentiated myoblasts, a PcG complex
formed by Ezh2, YY1 DNA binding protein and the deacetylase
HDAC1 is bound at muscle speciﬁc gene regulatory regions to
maintain chromatin silent and preventing premature transcription.
Their presence correlates with trimethylation of K27 of H3 histone.
Upon gene activation, Ezh2, HDAC1 and YY1 dissociate from
muscle loci, H3K27 becomes hypomethylated and MyoD and SRF
(Serum Response Factor) are recruited to chromatin, whereas
Ezh2 knock down causes premature expression of skeletal musclegenes and acceleration of myoblasts to myotubes switch program
[99,100]. As Ezh2 levels drop in myotubes, the question remains
opens about who is maintaining H3K27m3 and silencing in termi-
nally differentiated myotubes.
Thus, PcG-repressed system controls precocious induction of
genes during differentiation, allowing for integration of multiple
signals in a temporally ordered manner. To overcome PcG
repression asmuscle differentiation proceeds, it’s important to ana-
lyze the role and coordination of signalling pathways operating
with Polycomb proteins during skeletal muscle cell differentiation
that by changing epigenetic codes control correct activation of
developmentally regulated genes. Among the cofactors feeding into
the myogenic process, the p38 mitogen-activated protein kinase
(MAPK) is crucial in establishing the muscle speciﬁc gene expres-
sion program [101,102], whereas the role of the NF-kB pathway acts
both positive and negative [103–105]. The observation that muscle
speciﬁc genes are targeted for repression by PcG proteins suggests
that activation of these genes should require the antirepressive
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shown to be essential for the recruitment of SWI/SNF chromatin
remodelling complex to the Myog and CKm promoters (Fig. 2)
[106]. Further, Rampalli et al. [107] demonstrated that Myog and
CKm genes became epigenetically marked for gene expression
(H3K4me3) during muscle differentiation by recruiting TrxG
Ash2L–HMT complex. Targeting of Ash2L is mediated by the tran-
scriptional regulator Mef2d and this interaction is modulated
through activation of the p38 MAPK signalling pathway, via
phosphorylation of Mef2d. Furthermore, it has been shown that
Mef2d cooperates with myogenin to recruit SWI/SNF to the
promoter region of the CKm gene [108]. Thus SWI/SNF chromatin
remodelling complex appears to be recruited and to counteract
PcG at Myog and CKm promoters through different mechanisms.
In contrast to the activating role of p38-alpha in muscle gene
activation, p38-gamma represses MyoD transcriptional activity by
direct phosphorylation, via association with H3K9 methyltransfer-
ase KMT1A [109]. Thus, p38 kinases can either activate or repress
gene expression, depending on the engagement with speciﬁc p38
isoforms. Notably, recent data show that in satellite cells p38 sig-
nalling to PRC2 complex speciﬁcally directs the repression of genes
that are typically down-regulated duringmuscle differentiation, via
phosphorylation of Ezh2 (e.g. Pax7), but it has no direct impact on
PRC2-mediated repression of muscle speciﬁc genes [110], suggest-
ing that other pathways control PcG function in myoblast-myotube
transition.
To permit muscle gene activation, chromatin remodelling
complexes have to be recruited on muscle speciﬁc loci. At the same
time, also PcG complexes and repressive mark H3K27me3, have to
be displaced from their targets (Fig. 2). One way of doing it would
be to reduce HMT PcG intracellular levels. Juan et al. [100]
provided evidences that miR-214 can affect PcG complex gene
expression by regulating Ezh2 protein levels in skeletal muscle
and embryonic stem cell. Mice with experimental ablation of the
miR-199/214 locus display developmental defects, suggesting a
relevant role of these microRNAs in skeletal myogenesis [111]. Sev-
eral microRNA inﬂuence myogenesis [112]. In particular, miR26a
regulates Ezh2 in skeletal muscle cells and promote their differen-
tiation [113]. It is likely that miR-214 and miR-26a affect Ezh2 at
distinct developmental steps. Indeed, miR-214 accumulation is
evident at the very initial stages of cell differentiation-coinciding
with the initial and most evident Ezh2 protein reduction [100]-
whereas miR-26a could not be detected until SMC had completed
their terminal differentiation [113]. Recent studies open interest-
ing questions about the paradigm that PcG derepression has to
be accompanied by the loss of H3K27me3 repressive mark.
Seenundun et al. [114] showed that the histone demethylase
UTX is targeted to muscle speciﬁc genes by the transcriptional
activator Six4 to mediate removal of repressive H3K27me3 mark
during myogenesis (Fig. 2). However, a novel mechanism inducing
PcG chromatin displacement has recently been proposed.
Phosphorylation of H3Serine28 (H3S28ph), via mitogen and stress
activated kinases Msk1/2, is able to counteract the docking site
H3K27me3 determining the PcG chromatin removal and gene
activation, in response to stress signalling, mitogenic signalling
and retinoic acid (RA)-induced neuronal differentiation (Fig. 2)
[94,95]. Data from our lab show that a similar mechanism appears
to occur in differentiating myoblasts in which Msk1 regulates a
phosphomethyl H3S28ph/H3K27me3 switch to allow removal of
PRC2-Ezh2 complex and muscle gene activation (Stojic, Prezioso,
Jasencakova et al., unpublished data). Interestingly, our data show
that another PRC2 complex that includes Ezh1 subunit substitutes
for PRC2-Ezh2 and it is required in order to completemyogenic pro-
gram. A similar dynamics of Ezh2 being replaced by Ezh1 has been
reported in epidermis differentiation [51]. Notably, both in vivo and
in vitro chromatin binding experiments show that this complexis insensitive to H3S28ph, suggesting that Msk-phosphomethyl
switch pathway is speciﬁc for Ezh2 but not for PRC2 complex as
such (Stojic, Prezioso, Jasencakova et al., submitted).
The role of PcG epigenetic memory in terminally differentiated
myoﬁbers remains to be elucidated. To this PcG comprehensive
dynamics and genome-wide mapping analysis will be required to
decipher the link between signalling and PcG epigenetic regulation
during muscle differentiation.7. PcG-mediated epigenetic control of epidermal differentiation
The mammalian epidermis has turned out to be a highly infor-
mative model to explore the functional signiﬁcance and physiolog-
ical relevance of PcG-mediated chromatin repression during
embryonic tissue development and homeostasis. Epidermal line-
age originates from a single layer of multi-potent progenitors, ba-
sal cells, which adhere to an underlying basement membrane
separating epidermis from dermis [115]. Basal cells continually
fuel the production of  10 suprabasal layers. Once cells exit the
basal layer, they down-regulate proliferation-associated genes
and execute a terminal differentiation program that is marked by
a stepwise transcriptional transition from early differentiation spi-
nous layers to late differentiation granular layers. In the last step,
all metabolic activity ceases as dead squames of the protective
stratum corneum are formed and subsequently sloughed from
the skin surface. Maintaining the relative size of these compart-
ments requires that the cell proliferation rate in the basal
layer, the tendency of cells to survive versus differentiate in the
suprabasal layers and terminal cell death in the corniﬁed layer
be co-ordinately controlled and balanced [116].
Recent studies suggest that PcG gene products regulate these
processes at different levels, with a particular emphasis on
Bmi-1, a PRC1 subunit that acts as a cofactor in H2A ubiquitylation
by Ring1A/Ring1B [117]. Although Bmi-1 was characterized as a
stem cell maintenance protein that is required for efﬁcient renewal
of hematopoietic, leukemic and neuronal stem cells [118], in the
epidermis it does not appear to function exclusively as a stem cell
regulator. Indeed, if this were the case, one would expect expres-
sion to be restricted to epidermal stem cell compartment.
However, the available evidence suggests that Bmi-1 is localized
in the nucleus of proliferating keratinocytes and in the basal and
suprabasal layers [119,120] and is not strictly conﬁned to stem
cells [121–124]. These ﬁndings are consistent with a previous
report indicating a nuclear localization of this protein in ﬁbroblasts
[125] and this localization appears necessary for function, as Bmi-1
mutants that cannot localize in the nucleus are inactive [125].
Several studies suggest that the pro-survival, pro-proliferation
action of Bmi-1 may be due to its ability to suppress expression
of proteins that regulate cell cycle progression for example, the
Ink4a/Arf locus genes [118,126]. Senescence, the process whereby
aging cells gradually lose proliferation potential [127], is controlled
by the expression of products of Ink4a/Arf locus, p16INK4a and
p14ARF and Bmi-1 seems to play a key role in this context. Silva
et al. [119] showed that cells that have high proliferative potential
have high Bmi-1 and low p16INK4a [119,128]. This relationship is
also observed in aging epidermis, as Bmi-1 levels are high in kerat-
inocytes isolated from young individuals and lower in cells isolated
from older individuals [121,128]. In addition, Cordisco et al. [128]
found that the Bmi-1 levels are also reduced in keratinocytes
isolated from young xeroderma pigmentous group C, trichothl-
odystrophy, and progeria patients as compared with keratinocytes
isolated from healthy young individuals and lower levels are
present in keratinocytes derived from photo-aged epidermis than
those collected from non-exposed epidermis of the same patients.
Altogether, we can conclude that Bmi-1 has a role in controlling
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role of Bmi-1 in keratinocytes survival and proliferation was also
conﬁrmed by treatment with chemiopreventive agent or keratyno-
cyte differentiating/apoptosis-inducing agent, that reduces the
expression of Bmi-1 and other PcG proteins, such as Ezh2 and
Suz12 and also H3K27me3 levels [120,129]. An interesting ﬁnding
is that overexpression of Bmi-1 is associated with increased
expression of Ezh2, suggesting that Bmi-1 somehow functions to
maintain expression of the enzyme that prepares its chromatin
binding site, H3K27me3 [129]. While much is known about the
Bmi-1 role in controlling cell survival, little is known about its
involvement in apoptosis. Recent works show that Bmi-1 expres-
sion maintains survival of cells following challenge with stress
agent, such as OA, TPA, UVB [120,129]. Only one report has
addressed the possible role for Bmi-1 in regulating apoptosis, via
inhibition of Myc-dependent increase of p19ARF [130,131]. Other
PcG proteins have also been studied in epidermis, including the
PRC2 complex components, Ezh2, Suz12 and Ezh1. Interesting
evidence was reported in the work of Ezhkova et al. [51]. They
showed that Ezh2 is expressed in epidermal progenitors but
diminishes concomitant with embryonic differentiation and with
post-natal decline in proliferative activity. Loss of PcG function in
the developing skin alters epithelial stem cells proliferation and
accelerates the timing of skin development. Indeed, Ezh2, like
Bmi-1, controls proliferative potential of basal progenitors by
repressing Ink4a/Arf locus and tempers the developmental rate of
differentiation by preventing premature recruitment of Ap1
transcriptional activator to the structural genes that are required
for epidermal differentiation. In agreement with recent data [50],
also in epidermis while Ezh2 declines, Ezh1 levels increase in
upper and terminal differentiated layers [51].
Further analysis on the role of Ezh2 and Ezh1 in epidermis [52]
revealed new insight into tissue speciﬁc PcG-dependent control
and provided a new twist to how different progenitors within
the same tissue respond to loss of H3K27me3. Sen et al. [132]
showed that epigenetic derepression is controlled by Jmjd3 histone
demethylase during mammalian epidermal differentiation (Fig. 2).
Perhaps the most surprising ﬁnding of these studies was that the
global loss of H3K27me3 did not cause wide-spread differentiation
defects in epidermis. Thus, even though many PcG-repressed
differentiation genes [6] showed signs of transcriptional activation
in the absence of Ezh2/1, the levels of non-epidermal differentia-
tion programs were still low to reroute already established skin
fates [52]. These observations underscore the importance of
additional epigenetic modiﬁers and backup mechanisms (other
repressive histone marks, DNA methylation, non-coding RNA) that
appear to have evolved in complex organism to ensure the estab-
lishment and maintenance of lineage programs in adult tissues.
Mechanisms of tissue repair like wound healing are closely related
to processes that control development and cell proliferation. It is
interesting that three major components of the PRC2 complex,
Eed, Suz12 and Ezh2 are reduced in epidermis during wound heal-
ing [124]. In agreement with this observation, it has been reported
that in D. melanogaster the expression of the TrxG and PcG family
genes is modulated during transdetermination events [133].
Indeed, in fragmented imaginal discs-the determined structures
responsible for the development of the adult cuticular parts-some
PcG genes are downregulated in the proliferating cells at the
wound site upon activation of the Jun N-terminal kinase (JNK)
pathway [134]. Downregulation of PcG genes reduces the silencing
of the target genes and increases the plasticity by facilitating the
accessibility of the new transcription factors to developmental
regulator and pro-stem cell genes [135] as well as easing the
switch to new epigenetic imprints. These results appear to conﬂict
with the idea that PcG protein expression correlated with en-
hanced cell survival and increased expression of survival genes.However these ﬁndings highlight the potential complexity of the
epidermis regulation and suggest that the role of the PcG proteins
may be context dependent.
8. PcG cell memory function in neuronal differentiation
Although for long decades the adult brain had been thought to
represent an exception to the general concept that most adult
tissues retain a reservoir of self-renewing multipotent stem cells
generating differentiated tissue components, it’s now clear that
this organ also retains stem cells that produce neuronal cells
throughout life [136]. Neuronal stem cells (NSCs) are deﬁned as
cells that possess the ability to self-renew and to generate the
three major cell types in the central nervous system (CNS):
neurons, astrocytes and oligodendrocytes. NSCs and neurogenesis
persist throughout life in the subventricular zone (SVZ) and
dentate gyrus of the hippocampus. These differentiation processes
are deﬁned by the dynamic interplay between extracellular cues
including cytokine signalling and intracellular programmes such
as epigenetic modiﬁcations.
There is increasing evidence that the PcG group proteins are
closely associated with fate speciﬁcation of NSCs. These epigenetic
modiﬁers could represent a coordinated system for regulating gene
expression at each step of neuronal cell differentiation. The
dynamic gain and loss of PcG and TrxG-mediated histone modiﬁca-
tions occur during in vitro developmental progression from embry-
onic stem cells (ESCs) to fully differentiated neurons [88,137,138].
Using a murine system that progresses from stem cells to lineage-
committed progenitors to terminally differentiated neurons, Mohn
et al. [88] suggested a model how de novo DNA methylation and
dynamic switches in Polycomb targets restrict pluripotency and
deﬁne the developmental potential of progenitor cells. These obser-
vations are compatible with a role for Polycomb in targeting DNA
methyltransferase activity [139,140]. It’s important to consider that
both proneuronal bHLH and SoxC transcription factors (TFs)-
together involved in neuronal fate determination and differentia-
tion-seem to be regulated by a distinct temporal pattern of
PcG-mediated repression. The PcG-mediated repression of the
Sox2 promoter occurs during differentiation of neuronal progeni-
tors cells (NPCs) [88]. Unlike the pluripotency and multipotency
factor Sox2, developmental TFs, such as Ngn2, NeuroD1, NeuroD2,
Sox4 and Sox11 are repressed by a PcG-mediated mechanism
already in pluripotent ESCs. They all have bivalent promoters,
suggesting they are poised to be activated [80]. In multipotent
NPCs, Ngn1, Ngn2 and NeuroD2 retain the ‘‘closed’’ promoter
conformation, with H3K27me3 repressive mark, whereas promot-
ers of Sox4 and Sox11 become ‘‘open’’, losing H3K27me3 (Fig. 1)
[80,88,141]. Thus, these data suggest that PRC2-dependent marker
is related to changes in transcriptional programs associated with
transition from ES cell-derived NSCs to neuronal progenitors and
their differentiated progeny. The impact of PcG regulation on NSC
self-renewal is more limited and it is derived mostly from studies
in loss-of-function models of Bmi1. Knockout of Bmi1 has little ef-
fect on progenitor cell self-renewal during development but it is
essential for neuronal stem cell maintenance in the adult CNS
[118]. Moreover, Bmi1 is essential for cerebellar development and
it is overexpressed in human medulloblastoma [142]. Therefore,
Ring1B promotes embryonic NSC self renewal by sustaining their
proliferative activity and maintaining their undifferentiated state
and developmental potential [143]. Interestingly, Pereira et al.
[144] reported that Ezh2 is essential for controlling the rate at
which development progresses within cortical progenitor cells
lineages. Loss of function of Ezh2 removes H3K27me3 repressive
mark in cortical progenitor cells and also prevents its establishment
in post-mitotic neurons. This dynamics correlates with marked
up-regulation in gene expression, the consequence of which is a
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ward differentiation, both directly to neurons and indirectly via ba-
sal progenitor cell genesis. Although the temporal order of
neurogenesis and gliogenesis are broadly conserved under these
conditions, the timing of neurogenesis, the relative numbers of dif-
ferent cell types and the switch to gliogenesis are altered, narrow-
ing the neurogenic period for progenitor cells and reducing their
neuronal output. The ﬁndings reported here contrast with a recent
report about the consequence of Ring1B and of Ezh2 depletion in
the E12 cortex during neurogenic period [145]. Removal of Ring1B
from the developing cortex during neurogenesis lengthens the per-
iod of neurogenesis and delays the onset of oligogenesis [145].
Deletion of Ezh2 at the same developmental stage produces the
same phenotype [145]. This difference points to a potential role
for Polycomb in regulatingmajor developmental transition in corti-
cal progenitor cells: changing the competence of cortical progeni-
tors cell to generate neurons of different laminar fates; switching
from neurogenesis to gliogenesis. The requirement of Ezh2 in regu-
lating neurogenesis and differentiation appears to be in line with its
proposed role in maintaining stem cell populations, such as hema-
topoietic stem cells [146,147]. However, it is becoming clear that
the role of PRC2 ismore complex in this cell type. PRC2 not only acts
to promote self-renewal but also controls fate choices within this
multipotent lineage, so that in its absence neural progenitors cells
alter their fate decisions. Thework by Sher et al. [148] has been very
instrumental to better clarify the role of Ezh2 in the control of
neuronal differentiation programs. They reported that Ezh2 is
highly expressed in proliferating NSCs and its expression decreases
when the NSCs differentiates into neurons and it is completely
suppressed during differentiation into astrocytes. Surprisingly,
Ezh2 levels remain high in NSCs that differentiate into an oligo-
dendrocytic cell lineage. Depletion of Ezh2 in NPCs leads to a delay
in the differentiation capability to form oligodendrocytes. Thus,
identifying Ezh2 targets responsible for these altered progenitor
cell behaviour will provide crucial insights for neuronal progenitor
cell multipotency and other fate choices.
The observations reported until now that lineage speciﬁc genes
repressed by PcG-mediated H3K27me3 have to be derepressed in
differentiated cells postulated the existence of a speciﬁc
H3K27me3 demethylase. First evidence was reported in the work
of Burgold et al. [149]. They found that Jmjd3, recently identiﬁed
as a H3K27me3 speciﬁc demethylase which is recruited by H3K4
methyltransferase Mll1 [138,149,150], controls the expression of
key regulators and markers of neurogenesis and is required for
commitment to the neural lineage (Fig. 2). Thus, regulation of
H3K27me3 is highly gene- and context-speciﬁc, suggesting that
the interplay of methyltransferases and demethylases enables the
ﬁne-tuning more than the on/off alternation of methylated states.
A recent study added novel aspects to signal-dependent release of
PcG mediated silencing. Gehani et al. [94] proposed a model for
PcG protein displacement on gene promoters in response to
Msk-mediated H3K27me3S28 phosphorylation during retinoic
acid (RA)-induced neuronal differentiation (Fig. 2). As already
commented before (see Section 6), these data suggest that we have
to reconsider demethylation of H3K27me3 as the only mechanism
for gene derepression of PcG group protein-bound genes during
differentiation. Related to this, we need to understand if H3S28
phosphorylation affects H3K27 demethylation by JmjC family
members. If demethylation is blocked by S28 phosphorylation,
H3K27me3S28 phosphorylation mechanism for PcG displacement
speaks for a more transient nature of derepression as compared
to regions where H3K27me3 is removed by JmjC proteins. Further-
more, a recent report demonstrated that the Dnmt3a-dependent
non-proximal methylation promotes expression of neurogenic
genes by functionally antagonizing Polycomb repression [151].
Given that both DNA methylation and Polycomb pathways areindispensable for normal development and are implicated in
diseases, including neurological disorders and cancer [152,153], it
will be of interest to fully elucidate mechanisms by which these
two epigenetic machineries are targeted to speciﬁc genomic loci
and are cross-regulated.9. Concluding remarks
The studies reported in this review reinforce the concept that
cell differentiation is a dynamic and also reversible process, involv-
ing the concerted action of signalling pathways, transcription and
epigenetic factors. A long-standing notion in developmental biol-
ogy has been that organ/tissue speciﬁc stem cells are restricted
to differentiating into cell types of tissue in which they reside. In
other words, they have irreversibly lost the capacity to generate
other cell types in the body. However, recent evidences suggest
that tissue-speciﬁc stem cells may overcome their intrinsic line-
age-restriction upon exposure to a speciﬁc set of signals in vitro
and in vivo [154–161]. The transition from somatic cell to induced
pluripotent stem cell (iPS cell) involves radical alterations in the
epigenetic landscape of the cell. The epigenetic signature of iPS
cells resembles but is not identical to the epigenetic signature of
embryonic stem cells [162–164]. For this reason, iPS cells retain
an epigenetic memory of their somatic progenitors. The impor-
tance of PcG proteins in this context is strongly represented in
the work of Pereira et al. [165] in which they showed that ESCs
require PRC2 components to direct the successful reprogramming
of differentiated cells toward pluripotency. Thus, the differentia-
tion of progenitor cells into terminally differentiated cell types
and the de-differentiation of somatic cells into progenitor cells
are governed by epigenetic functions. The loss of cellular memory
is a crucial step not only for reprogramming events but also in the
cancer, in which cells appear to forget their lineage features and
re-acquire aggressive proliferative potential. PRC2 components
are upregulated in various cancers such as melanoma, lymphoma,
breast and prostate cancer. In particular Ezh2 has been reported to
be not just a marker but also a major player in the aggressive
stages of a large number of tumors [166–169]. Thus, unravelling
the molecular basis of cell memory will be crucial for the compre-
hension of fundamental aspects of the biology cell differentiation
as well as complex diseases like cancer, in which loss of cell mem-
ory can be eventually fatal.
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